MDCX: Robust Phase 2 Data Moves SkinJect Closer to Non-Surgical Care for Basal Cell Carcinoma

Strong 73% Clinical Clearance Seen in Key Phase 2 Cohort

Medicus Pharma Ltd. (NASDAQ:MDCX) made headlines today after providing new details on its recent Phase 2 results for SkinJect – a novel microneedle patch that targets basal cell carcinoma (BCC). In its SKNJCT-003 study, the standout finding was a 73% clinical clearance and 40% histological clearance at Day 57 in the 200-g treatment group, marking the highest efficacy within the trial.

To put it simply: nearly three out of four lesions treated with the drug-loaded microneedle patch visually cleared without surgical intervention, while 40% showed no evidence of tumor under biopsy. With BCC representing the most common cancer globally, these results position SkinJect as a promising non-surgical treatment alternative for millions of patients.

Data Tables Highlight Clinical Impact

The results above underscore a key point: the SkinJect patch, even in its placebo (P-MNA) arm, showed some biological activity—38% of lesions achieved visual clearance. This supports literature that microneedle-induced micro-injury can help trigger immune and wound-healing responses, contributing to BCC regression even without active drug. However, the much higher clearance rate in the active arm (D-MNA) sets a clear benefit for the drug-loaded patch strategy.

Therapeutic and Real-World Potential: Less Surgery, More Options

These findings are significant for patient care. In practice, dermatologists typically opt for surgery to clear BCC lesions, especially in repetitive or high-risk cases like Gorlin Syndrome. SkinJect's promising results raise the prospect of minimizing repeated surgeries, reducing patient discomfort and risk of disfigurement. For rare conditions with a high frequency of tumors, a patch-based approach could transform management.

Importantly, Medicus Pharma is not standing still. The company has already secured UK regulatory and ethical approvals to expand the study, completed U.S. enrollment for Phase 2, and aims to move swiftly to a pivotal end-of-Phase-2 FDA meeting in the first half of 2026. Additionally, a partnership with the Gorlin Syndrome Alliance is underway, prioritizing wider, compassionate access for at-risk patients pending further trials.

Next Steps: Regulatory Pathways and Strategic Partnerships

With decision-grade evidence in hand, Medicus plans to discuss optimal registration strategies with the FDA, exploring further dose optimization, patch duration tuning, and expanded treatment sessions. The company sees these advances supporting licensing or partnerships with established pharma players in dermatology and oncology.

Management Sees Strong Foundation for Growth

Dr. Raza Bokhari, Executive Chairman and CEO, endorsed the results as a foundation for future regulatory and commercial moves, underscoring the potential for SkinJect to redefine BCC care. This approach—phase 2 de-risking combined with targeted partnering—reflects Medicus Pharma’s broader growth strategy across its innovative pipeline, including advanced prostate cancer programs and AI-driven clinical analytics collaborations.

Key Takeaway: Decision-Grade Data and Broad Momentum

In summary, Medicus Pharma’s Phase 2 SkinJect dataset not only sets new benchmarks for non-surgical BCC treatment but also accelerates the company toward regulatory filings and potential strategic collaborations. Investors and clinicians alike may want to watch the upcoming FDA interactions and partnership developments as Medicus works to turn skin cancer’s most common challenge into an opportunity for less invasive, more accessible, and patient-friendly care.

Contact Highlights and Recent Milestones

• Phase 2 study enrolled 90 U.S. patients; UK approvals received.
• End-of-Phase-2 FDA meeting targeted for 1H 2026.
• Strategic alliances—Gorlin Syndrome (compassionate access) and AI-driven analytics—for expanded reach and data-driven development.
• Further collaborations in prostate cancer and women’s health under development.

For a full breakdown of Medicus Pharma’s clinical updates and long-term strategy, see the latest press release or reach out to their investor relations team.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI